Long-Term Treatment of Postmenopausal Osteoporosis

Overview

Journal Endocrinol Metab (Seoul)

Specialty Endocrinology

Date 2021 Jun 21

PMID 34154042

Citations 49

Authors

Jacques P Brown

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is an incurable chronic condition, like heart disease, diabetes, or hypertension. A large gap currently exists in the primary prevention of fractures, and studies show that an estimated 80% to 90% of adults do not receive appropriate osteoporosis management even in the secondary prevention setting. Case finding strategies have been developed and effective pharmacological interventions are available. This publication addresses how best to use the pharmacological options available for postmenopausal osteoporosis to provide lifelong fracture protection in patients at high and very high risk of fracture. The benefit of osteoporosis therapies far outweighs the rare risks.

Citing Articles

Burden and trends of facial fractures in China and the United States based on GBD 2021 analysis.

Chen H, Jia Z, He X, Feng X, Wu M, Zhang S Sci Rep. 2025; 15(1):8328.

PMID: 40064970 PMC: 11894044. DOI: 10.1038/s41598-025-92980-z.

Ancient Medicinal Insect (Boleny)-Derived Extracellular Vesicle-Like Particles Enhances Autophagic Activity to Promote Osteogenic Differentiation via Melatonin in Osteoporosis.

Lu J, Chen J, Jiang Y, Liu Y, Yu S, Shi Z Int J Nanomedicine. 2025; 20:2059-2071.

PMID: 39975419 PMC: 11835776. DOI: 10.2147/IJN.S505443.

Association between female reproductive characteristics and bone mineral density: evidence from Mendelian randomization.

Yang S, Zhu L, Luo F, Jiang R, Yu L Arch Med Sci. 2025; 20(6):2063-2066.

PMID: 39967930 PMC: 11831361. DOI: 10.5114/aoms/199623.

Effect of salmon calcitonin combined with calcium antagonist on blood calcium and phosphorus ion concentration in osteoporosis rats.

Chen J, Wang J, Jia W, Zhang Y, Li H, Liu S Eur J Med Res. 2025; 30(1):115.

PMID: 39966992 PMC: 11834539. DOI: 10.1186/s40001-025-02384-y.

Association of the various physical activity patterns with low bone mineral density in Americans aged 20-60.

Wang Y, Long L, Liu L, Fan P, Zheng X, Li X Arch Osteoporos. 2025; 20(1):23.

PMID: 39945926 DOI: 10.1007/s11657-024-01479-z.

References

Kim H, Jang E, Park B, Kim T, Shin S, Ha Y . Development of a Korean Fracture Risk Score (KFRS) for Predicting Osteoporotic Fracture Risk: Analysis of Data from the Korean National Health Insurance Service. PLoS One. 2016; 11(7):e0158918. PMC: 4939957. DOI: 10.1371/journal.pone.0158918. View

Miller P, Pannacciulli N, Brown J, Czerwinski E, Nedergaard B, Bolognese M . Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. J Clin Endocrinol Metab. 2016; 101(8):3163-70. PMC: 4971333. DOI: 10.1210/jc.2016-1801. View

McCloskey E, Kanis J, Johansson H, Harvey N, Oden A, Cooper A . FRAX-based assessment and intervention thresholds--an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int. 2015; 26(8):2091-9. DOI: 10.1007/s00198-015-3176-0. View

Ng A, Png M, Mohan P, Koh J, Howe T . Atypical femoral fractures: transverse morphology at lateral cortex is a critical feature. J Bone Miner Res. 2013; 29(3):639-43. DOI: 10.1002/jbmr.2078. View

Metcalfe D, Zogg C, Judge A, Perry D, Gabbe B, Willett K . Pay for performance and hip fracture outcomes: an interrupted time series and difference-in-differences analysis in England and Scotland. Bone Joint J. 2019; 101-B(8):1015-1023. PMC: 6683232. DOI: 10.1302/0301-620X.101B8.BJJ-2019-0173.R1. View

Mitchell P . Best practices in secondary fracture prevention: fracture liaison services. Curr Osteoporos Rep. 2013; 11(1):52-60. DOI: 10.1007/s11914-012-0130-3. View

Brown J, Morin S, Leslie W, Papaioannou A, Cheung A, Davison K . Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014; 60(4):324-33. PMC: 4046542. View

Adler R, Fuleihan G, Bauer D, Camacho P, Clarke B, Clines G . Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2015; 31(1):16-35. PMC: 4906542. DOI: 10.1002/jbmr.2708. View

Watts N, Grbic J, Binkley N, Papapoulos S, Butler P, Yin X . Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. J Clin Endocrinol Metab. 2019; 104(6):2443-2452. DOI: 10.1210/jc.2018-01965. View

10.

Cummings S, Ferrari S, Eastell R, Gilchrist N, Jensen J, McClung M . Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2017; 33(2):190-198. DOI: 10.1002/jbmr.3337. View

11.

Bone H, Bolognese M, Yuen C, Kendler D, Miller P, Yang Y . Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011; 96(4):972-80. DOI: 10.1210/jc.2010-1502. View

12.

Black D, Reid I, Boonen S, Bucci-Rechtweg C, Cauley J, Cosman F . The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2011; 27(2):243-54. PMC: 3427916. DOI: 10.1002/jbmr.1494. View

13.

Adachi J, Loannidis G, Berger C, Joseph L, Papaioannou A, Pickard L . The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int. 2002; 12(11):903-8. DOI: 10.1007/s001980170017. View

14.

Johansson H, Siggeirsdottir K, Harvey N, Oden A, Gudnason V, McCloskey E . Imminent risk of fracture after fracture. Osteoporos Int. 2016; 28(3):775-780. PMC: 5338733. DOI: 10.1007/s00198-016-3868-0. View

15.

Burden A, Tanaka Y, Xu L, Ha Y, McCloskey E, Cummings S . Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review. Osteoporos Int. 2020; 32(5):817-829. PMC: 8043871. DOI: 10.1007/s00198-020-05756-8. View

16.

Bell A, Hill M, Herman R, Girard M, Cohen E . Management of atherothrombotic risk factors in high-risk Canadian outpatients. Can J Cardiol. 2009; 25(6):345-51. PMC: 2722477. DOI: 10.1016/s0828-282x(09)70088-1. View

17.

Kanis J, Johansson H, Harvey N, Gudnason V, Sigurdsson G, Siggeirsdottir K . The use of 2-, 5-, and 10-year probabilities to characterize fracture risk after a recent sentinel fracture. Osteoporos Int. 2020; 32(1):47-54. DOI: 10.1007/s00198-020-05700-w. View

18.

Brenneman S, Barrett-Connor E, Sajjan S, Markson L, Siris E . Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res. 2006; 21(6):809-16. DOI: 10.1359/jbmr.060301. View

19.

Khan A, Morrison A, Hanley D, Felsenberg D, McCauley L, ORyan F . Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2014; 30(1):3-23. DOI: 10.1002/jbmr.2405. View

20.

Eastell R, Hannon R, Wenderoth D, Rodriguez-Moreno J, Sawicki A . Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab. 2011; 96(11):3367-73. PMC: 3205892. DOI: 10.1210/jc.2011-0412. View